文献速递神经肿瘤

手术切除的低级别胶质瘤中辅助放疗 alone 与化疗 alone 的比较:来自美国国家癌症数据库2253例的生存分析

Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base.
PubMed 文献 · World Neurosurg · 2018-01-31

基于美国国家癌症数据库2004至2013年2253例组织学确诊的世界卫生组织2级胶质瘤术后患者,比较单独放疗(1466例,65.1%)与单独化疗(787例,34.9%)的生存。多变量分析显示单独化疗较单独放疗与显著更长的总生存相关(HR 0.405,95%CI 0.277-0.592,P<0.001),倾向评分匹配后结果一致(HR 0.612,95%CI 0.506-0.741,P<0.001)。作者认为单独化疗与更长总生存独立相关。

要点

  • 2253例WHO 2级胶质瘤术后患者中,单独放疗1466例(65.1%),单独化疗787例(34.9%)。
  • 单独放疗组中位总生存98.9个月,单独化疗组125.8个月。
  • 多变量分析单独化疗较单独放疗与显著更长的总生存相关(HR 0.405,95%CI 0.277-0.592,P<0.001)。

核心结论

  • 作者认为在手术后的低级别胶质瘤患者中,单独化疗较单独放疗与更长的总生存独立相关。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库识别2004至2013年组织学确诊的世界卫生组织2级胶质瘤术后接受单独放疗或单独化疗的患者。
  • 共纳入2253例患者,其中单独放疗1466例(65.1%),单独化疗787例(34.9%)。
  • 采用Kaplan-Meier分析、多变量Cox比例风险回归和倾向评分匹配分析评估总生存。

主要发现

  • 单独放疗组中位总生存为98.9个月,单独化疗组为125.8个月。
  • 多变量分析中,单独化疗较单独放疗与显著的总生存获益相关(HR 0.405,95%CI 0.277-0.592,P<0.001)。
  • 亚组分析中,单独化疗较单独放疗的生存优势在所有年龄组以及次全切除和活检组中持续存在,但在全切除组中不存在。
  • 倾向评分匹配分析中,单独化疗较单独放疗仍显示显著改善的总生存(HR 0.612,95%CI 0.506-0.741,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is becoming increasingly common to incorporate chemotherapy (CT) with radiotherapy (RT) in the treatment of low-grade gliomas (LGGs) after surgical resection. However, there is a lack of literature comparing survival of patients who underwent RT or CT alone. METHODS: The U.S. National Cancer Data Base was used to identify patients with histologically confirmed, World Health Organization grade 2 gliomas who received either RT alone or CT alone after surgery from 2004 to 2013. Overall survival (OS) was evaluated by Kaplan-Meier analysis, multivariable Cox proportional hazard regression, and propensity-score-matched analysis. RESULTS: In total, 2253 patients with World Health Organization grade 2 gliomas were included, of whom 1466 (65.1%) received RT alone and 787 (34.9%) CT alone. The median OS was 98.9 months for the RT alone group and 125.8 months for the CT alone group. On multivariable analysis, CT alone was associated with a significant OS benefit compared with RT alone (hazard ratio [HR], 0.405; 95% confidence interval, 0.277-0.592; P < 0.001). On subgroup analyses, the survival advantage of CT alone over RT alone persisted across all age groups, and for the subtotal resection and biopsy groups, but not in the gross total resection group. In propensity-score-matched analysis, CT alone still showed significantly improved OS compared with RT alone (HR, 0.612; 95% confidence interval, 0.506-0.741; P < 0.001). CONCLUSIONS: Our results suggest that CT alone was independently associated with longer OS compared with RT alone in patients with LGGs who underwent surgery.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wu J, Neale N, Huang Y, et al. Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base. World Neurosurg. 2018. PMID: 29409888. doi:10.1016/j.wneu.2018.01.163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。